Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp., trading under the ticker DMAAR, is a blank-check company targeting the domestic pharmaceutical manufacturing and life sciences sector. The company filed an 8-K with the SEC on May 5, 2026, accession number 0001213900-26-052324, reflecting a material corporate development in its lifecycle as a SPAC. The vehicle's name signals an explicit focus on U.S.-based drug production and supply-chain reshoring themes that have drawn investor attention in recent years. Sponsor details were not disclosed in the filing header. For the complete filing history, deal timeline, and sponsor profile for DMAAR, sign up for full data access at SpacDesk.